Sector News

Sanofi drops the ax on 100 R&D staffers in Boston reorganization

February 11, 2015
Life sciences
Just as it was spreading word of a big new development partnership this morning, Sanofi dropped the ax on about 100 employees in a reorganization of its R&D operations.
 
Rumors of the layoffs started circulating in the big Boston biotech hub later in the morning, and a spokesperson for Sanofi ($SNY) confirmed the cuts to FierceBiotech mid-day. The company made its cuts in oncology and global R&D, he said, sending word internally this morning.
 
“Sanofi communicated a natural evolution of its research and development organization that will prioritize its focus and investments in exciting areas of science and medicine,” according to a company statement.
 
The layoffs in oncology mark an acknowledgement of Sanofi’s struggle to develop new cancer treatments. Bloomberg reports that Tal Zaks, who had led the group, is out in the reorganization. And the wire service adds that oncology is being absorbed into global R&D as it tries to catch the next wave in cancer drug development.
 
Sanofi has faced considerable turmoil in recent months, after CEO Chris Viehbacher was suddenly ousted following a cut in the company’s forecasted revenue, a move that left Chairman Serge Weinberg in charge and in search of a new CEO. Sanofi spent more than $20 billion to acquire Genzyme almost exactly four years ago, carving out a big place for itself in the Boston/Cambridge supercluster. But Sanofi also faced the embarrassing writeoff of iniparib in 2013, an early sign that the company’s cancer R&D strategy was going astray.
 
Sanofi has had a mixed record in R&D since Viehbacher set out on a campaign to reorganize the company, becoming a proponent for major changes after seeing little in the way of innovation. An attempt to make cuts in France, though, was blunted by government and union officials. Internal R&D overall has a poor track record. Where Sanofi has performed well is in partnering, with a very close relationship with Regeneron that has paid off with some closely watched development efforts.
 
Sanofi followed up with new collaborations, like the one announced today with Voyager Therapeutics to explore new gene therapies for CNS diseases. That deal included $100 million upfront, and up to $745 million in milestones.
 
By John Carroll
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.